GenFleet Therapeutics (Shanghai) (HKSE:02595) EBIT: HK$-1,967.1 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02595 GenFleet Therapeutics (Shanghai) Inc HKSE:02595
10 GF Score
Price HK$27.60
! 3 Warning Signs
View Full Analysis

What is GenFleet Therapeutics (Shanghai) EBIT?

GenFleet Therapeutics (Shanghai) HKSE:02595 +1.85% 10 EBIT is HK$-1,967.1 Mil as of Dec. 2025. GuruFocus rates HKSE:02595 with a GF Score™ of 10/100. The stock has 3 warning signs investors should review.

GenFleet Therapeutics (Shanghai)'s earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was HK$-1,206.8 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-1,967.1 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. GenFleet Therapeutics (Shanghai)'s annualized ROC % for the quarter that ended in Dec. 2025 was -23.13%. GenFleet Therapeutics (Shanghai)'s annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -9,837.90%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. GenFleet Therapeutics (Shanghai)'s Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -23.67%.

GenFleet Therapeutics (Shanghai)  (HKSE:02595) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

GenFleet Therapeutics (Shanghai)'s annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-419.518 * ( 1 - 0% )/( (3335.532 + 291.594)/ 2 )
=-419.518/1813.563
=-23.13 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=603.285 - 117.736 - ( 400.633 - max(0, 3416.295 - 566.312+400.633))
=3335.532

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2425.537 - 154.275 - ( 2291.957 - max(0, 408.185 - 2387.853+2291.957))
=291.594

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

GenFleet Therapeutics (Shanghai)'s annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-2413.68/( ( (25.02 + max(-3160.53, 0)) + (24.049 + max(-219.346, 0)) )/ 2 )
=-2413.68/( ( 25.02 + 24.049 )/ 2 )
=-2413.68/24.5345
=-9,837.90 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(105.912 + 1.01 + 57.444) - (117.736 + 0 + 3207.16)
=-3160.53

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(17.586 + 19.152 + 53.34) - (154.275 + 0 + 155.149)
=-219.346

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

GenFleet Therapeutics (Shanghai)'s Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-1967.119/8309.803
=-23.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GenFleet Therapeutics (Shanghai) EBIT Related Terms

GenFleet Therapeutics (Shanghai) EBIT Historical Data

* Premium members only.

The historical data trend for GenFleet Therapeutics (Shanghai)'s EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GenFleet Therapeutics (Shanghai) EBIT Chart

GenFleet Therapeutics (Shanghai) Annual Data
Trend Dec23 Dec24 Dec25
EBIT
-554.37 -716.96 -1,975.23

GenFleet Therapeutics (Shanghai) Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
EBIT 0.00 -480.73 -240.20 -760.28 -1,206.84

HKSE:02595 vs VRTX, REGN, RVMD: EBIT Comparison

For the Biotechnology subindustry, GenFleet Therapeutics (Shanghai)'s EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GenFleet Therapeutics (Shanghai) EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GenFleet Therapeutics (Shanghai)'s EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where GenFleet Therapeutics (Shanghai)'s EV-to-EBIT falls into.


HKSE:02595
10GF Score
GenFleet Therapeutics (Shanghai) Inc HKSE:02595
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GenFleet Therapeutics (Shanghai) EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-1,967.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of HK$-1,967.1 Mil mean?
GenFleet Therapeutics (Shanghai) (HKSE:02595) has a EBIT of HK$-1,967.1 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on GenFleet Therapeutics (Shanghai).
Is GenFleet Therapeutics (Shanghai)'s EBIT too high?
GenFleet Therapeutics (Shanghai)'s current EBIT is HK$-1,967.1 Mil. Overall, GenFleet Therapeutics (Shanghai) has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does GenFleet Therapeutics (Shanghai)'s EBIT compare to VRTX and REGN?
GenFleet Therapeutics (Shanghai)'s EBIT of HK$-1,967.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on GenFleet Therapeutics (Shanghai). GenFleet Therapeutics (Shanghai)'s current EBIT is HK$-1,967.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GenFleet Therapeutics (Shanghai) stock overvalued right now?
GenFleet Therapeutics (Shanghai) (HKSE:02595) has a current EBIT of HK$-1,967.1 Mil. The current EBIT is HK$-1,967.1 Mil. GenFleet Therapeutics (Shanghai)'s overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For GenFleet Therapeutics (Shanghai) (HKSE:02595), the current EBIT is HK$-1,967.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GenFleet Therapeutics (Shanghai) Business Description

Other Exchanges Y3L:Germany
Address 1206 Zhangjiang Road, Floors 2nd, 3rd, 4th, and 5th, Building 8, Shanghai Pilot Free Trade Zone, Shanghai, CHN, 201203
GenFleet Therapeutics (Shanghai) Inc Company is a clinical-stage biotechnology company. The Company and its subsidiaries are principally engaged in the research, development and commercialisation of pharmaceutical products. The Group is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment.
10GF Score

Get the complete analysis for HKSE:02595

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$27.60
Price